Los Angeles, United States
Partillion Bioscience, founded in 2020 and headquartered in the United States, is an innovative player in the Biotechnology and Health Care sectors. With the mission of "Democratizing Single-Cell Biotechnology", the company is carving out a niche with its cutting-edge nanovial platform, which enables rapid and large-scale analysis of single cells. This technology aims to streamline the exploration of biological functions, such as protein secretion, and has received accolades in reputable journals like Science Advances and Lab on Chip.
In a positive momentum phase, Partillion Bioscience secured a $5.00M Seed Round of investment on 26 September 2023. The notable investors in this round included Paladin Capital Group, ND Capital, and Vertical Venture Partners. This backing from prominent financial supporters underscores the significant potential and innovative thrust of Partillion's proprietary technology in transforming single-cell assay accessibility.
